Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow WAT
Waters Corporation (WAT) Return on equity
Waters Corporation's return on equity over the twelve months to 30 June 2026 was 1.92%, down 27.4 percentage points from fiscal 2025 (29.3%). Over the past ten years it has ranged from 0.90% (fiscal 2017) to 6,576.7% (fiscal 2020); the current reading is higher than 36% of that period. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 29.3% | (13.54) |
| FY2024 | 42.8% | (34.80) |
| FY2023 | 77.6% | (84.70) |
| FY2022 | 162.3% | (68.74) |
| FY2021 | 231.1% | (6,345.59) |
| FY2020 | 6,576.7% | 6,488.98 |
| FY2019 | 87.7% | 56.43 |
| FY2018 | 31.2% | 30.34 |
| FY2017 | 0.90% | (23.02) |
| FY2016 | 23.9% | 0.19 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. compare | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| LH Labcorp Holdings Inc. compare | 11.7% |
| WAT Waters Corporation | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on WAT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement